Primary Care Clinics in Mason, TX Accepting Medicare
3 Primary Care Clinics found. Showing 1 - 3
 Frontera Healthcare Network Clinic/Center Medicare: Medicare Enrolled Practice Location: 216 W College Ave, Mason, TX 76856 Phone: 325-347-5926 Fax: 325-347-5331 |
El Campo Memorial Hospital Family Medicine Medicare: Medicare Enrolled Practice Location: 626 N Avenue F, Mason, TX 76856 Phone: 979-543-5510 |
Mason Rural Health Clinic Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 216 E College, Mason, TX 76856 Phone: 325-347-5926 Fax: 325-347-5331 |
News Archive
Opexa's Tovaxin for MS is now Tcelna
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
New study improves safety conditions during laparoscopic operations to avoid contagion by COVID-19
A team of researchers from the Department of Medicine of the Universitat Jaume I and health professionals from the Multidisciplinary Unit of Abdominopelvic Oncological Surgery together with the rest of the services that make up the surgical block of the General University Hospital of Castellón, have carried out a study (CovidLap) that has improved safety conditions during laparoscopic interventions to avoid contagion by COVID-19 among both health personnel and patients.
USC: Heavy traffic corridors responsible for preventable childhood asthma
Heavy traffic corridors in the cities of Long Beach and Riverside are responsible for a significant proportion of preventable childhood asthma, and the true impact of air pollution and ship emissions on the disease has likely been underestimated, according to researchers at the University of Southern California (USC).
Ranibizumab trial gets promising results for CNV
Patients with visual impairment due to myopic choroidal neovascularisation achieve better visual acuity after 3 months of individualised treatment with ranibizumab than with verteporfin photodynamic therapy, show the results of a phase III randomised controlled trial.
› Verified 6 days ago